Table 4 Treatment-emergent adverse events reported in ≥5 % of subjects in the teduglutide group
Variable, n (%) | Placebo (n = 13) | Teduglutide 4 mg (n = 23) |
|---|---|---|
Treatment-emergent AEs | 9 (69) | 14 (61) |
Abdominal distention | 2 (15) | 8 (35) |
Constipation | 2 (15) | 5 (22) |
Headache | 2 (15) | 5 (22) |
Abdominal pain | 1 (8) | 5 (22) |
Nausea | 0 | 5 (22) |
Dyspepsia | 0 | 2 (9) |
Eructation | 0 | 2 (9) |
Extremity pain | 0 | 2 (9) |